• Cervomed posted a net loss of $7.96 million for the three months ended March 31, 2026, widening 63% from a year earlier.
• Operating loss widened to $8.11 million, driven by no grant revenue versus $1.92 million a year earlier.
• Total operating expenses rose 12% to $8.11 million, with research and development up 6% to $5.14 million.
• General and administrative costs climbed 25% to $2.98 million, while interest income fell 64% to $147,387.
• Cash, cash equivalents, and marketable securities totaled about $12.9 million at March 31, 2026; management said this is not expected to fund operations for at least 12 months, and the company continues to plan a Phase 3 DLB trial subject to funding.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-017236), on May 15, 2026, and is solely responsible for the information contained therein.